AbbVie is a global biopharmaceutical company that focuses on the research, development, and commercialization of advanced therapies to treat complex diseases across multiple therapeutic areas, including immunology, oncology, neuroscience, and virology. The company is known for its innovative biologics and pharmaceutical products aimed at addressing unmet medical needs, improving patient outcomes, and enhancing the quality of life for individuals suffering from chronic and acute health conditions. Through a combination of scientific expertise and strategic partnerships, AbbVie continuously strives to push the boundaries of medical science and expand its portfolio of leading-edge treatments. Read More
Shares of pharmaceutical company AbbVie (NYSE:ABBV) jumped 4.4% in the morning session after the company announced it settled litigation with generic drug manufacturers to extend patent protection for its blockbuster autoimmune drug, RINVOQ. The agreement prevents generic competition for the drug in the U.S. until at least April 2037, a significant victory for the company. This extension provides about five more years of market exclusivity than some analysts had previously expected. RINVOQ is a crucial growth driver for AbbVie, especially as it manages lost revenue from its former mega-blockbuster, Humira. The drug's sales have been climbing rapidly, reaching $6 billion the previous year and are forecast to potentially hit peak sales of over $12 billion. This settlement secures a major future revenue stream for the company.
Wondering which stocks are making significant price gaps? Explore the S&P500 index on Thursday to find the gap up and gap down stocks in today's session.
The global economy is bracing for a significant slowdown, with leading financial institutions projecting a challenging landscape for 2025 and the years to follow. A confluence of escalating trade tensions, persistent policy uncertainty, and tighter financial conditions is converging to paint a picture of decelerated growth, raising concerns about job
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance.
Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.
AbbVie currently trades at $207.60 per share and has shown little upside over the past six months, posting a small loss of 0.7%. The stock also fell short of the S&P 500’s 9.2% gain during that period.
Health care saw some of the worst losses this year. But as the calendar turned to August, it's been leading the market higher. This ETF provides exposure.
